DefinitionThis section has been translated automatically.
Receptor selective acetylene retinoid.
Half-lifeThis section has been translated automatically.
2-19 minutes or 1-2 h (metabolites).
You might also be interested in
Pharmacodynamics (Effect)This section has been translated automatically.
Tazarotene binds like other retinoids to tissue-specific retinoid receptors (RAR = retinoic acid receptor and RXR = retinoid X receptor). This leads to modulations in the TIG-3 (Tazarotene induced gene 3) coding sequences.
IndicationThis section has been translated automatically.
- Approved indication: mild to moderate psoriasis vulgaris of the plaque type, see isotretinoin below.
- Newer non-approved indications are actinic keratoses and basal cell carcinomas of the superficial type (off-label use).
Dosage and method of useThis section has been translated automatically.
Apply gel 1 time per day to the affected areas.
Standard concentrationThis section has been translated automatically.
Gel: 0.05-0.1%.
ContraindicationThis section has been translated automatically.
Pregnancy.
PreparationsThis section has been translated automatically.
ZORAC®0 .1% gel
Note(s)This section has been translated automatically.
On April 25, 2019, the combination tazarotene with halobetasol propionate, DUOBRII Lotion, 0.01%/0.045% , will receive FDA approval for adults with plaque psoriasis. No approval in Europe
LiteratureThis section has been translated automatically.
- Bianchi L et al (2003) Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 149: 207-209
- Higuchi E et al (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 24: 4627-4635
- Jones PH et al (2003) A phase 1 study of tazarotene in adults with advanced cancer. Br J Cancer 89: 808-815
- Spuls P et al (2003) Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat 14(Supplement 2: 21-25
- Tokumaru Y et al (2003) Is TIG1 a new tumor suppressor in prostate cancer? J Natl Cancer Inst 95: 919-920
- Veraldi S, Schianchi R (2003) Short-contact therapy with tazarotene in psoriasis vulgaris. Dermatology 206: 347-348
- Lebwohl MG et al (2021) A. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol Venereol.;35:1152-1160.
Prof. Dr. med. Peter Altmeyer